Pfizer (NYSE: PFE) reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for ...

AstraZeneca (LSE: AZN) has launched FluMist Home, the first FDA-approved influenza vaccine program that allows self- or ...

Japan’s Mochida Pharmaceutical has announced that Lialda (mesalazine 600mg) the will be launched on September 8, 2025, as the NHI (National Health Insurance) Drug Price was listed on August 14, 2025.